Corning Incorporated vs Medpace Holdings Inc — how do they compare? Corning Incorporated trades at $167.44 (market cap $137.12B), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Corning Incorporated is far larger — about 8.1× Medpace Holdings Inc's market cap, and Corning Incorporated pays a 0.7% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| GLW | MEDP | |
|---|---|---|
Market Cap | $137.12B | $16.90B |
Sector | Technology | Technology |
52-Week High | $255.79 | $620.59 |
52-Week Low | $64.52 | $393.42 |
Enterprise Value | $144.00B | $16.52B |
Dividend Yield | 0.7% | — |
Signals from Pluang's Aura AI — not financial advice
Corning (GLW) trades at $167.02, up 5.88% over 24 hours, with a bearish technical signal but strong fundamental momentum. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS up 30% year-over-year. Revenue growth is accelerating, driven by optical communications and AI data center demand, though valuation multiples remain elevated. Recent news highlights analyst upgrades citing improved fundamentals post-sell-off.
Outlook is positive with a consensus price target of $193.33 (15.8% upside), supported by AI infrastructure growth and profitability improvements. Risks include high valuation sensitivity, competitive pressures, and execution challenges in scaling solar and automotive segments. Institutional sentiment is bullish with 56.75% buy ratings, but technical indicators warn of near-term overbought conditions.
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →